UNSPSC 51401546: Quazepam

This classification denotes a benzodiazepine with the molecular formula C17H11ClF4N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JF8V0828ZI, chemically known as 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2h-1,4-benzodiazepine-2-thione but generally known as quazepam, which bears US NIH Compound Identifier 4999. European Medicines Agency schedules Quazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10188MIG.

UNSPSC 51401546 Quazepam is a Commodity code for pharmaceutical products, but recent state and local procurement activity under this code does not align with quazepam specifically—instead, the tagged opportunities reflect broader pharmaceutical procurement including naloxone, generic multi-source drugs, and OTC products. State and local governments use this code family for purchases of prescription medications, over-the-counter pharmaceuticals, and emergency medical supplies to support public health initiatives, hospital systems, and community health programs. Issuing bodies include county health departments, state HHS agencies, and cooperative purchasing alliances serving multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a standout repeat buyer establishing multi-year contracts with manufacturers of generic pharmaceuticals and OTC products for distribution across member states and local facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence solicitation exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. MMCAP released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026, and awards effective July 1, 2026. All three opportunities require compliance with federal pharmaceutical regulations, including the Drug Supply Chain Security Act and FDA requirements, and establish multi-year terms with renewal or extension options.